CITRIS Foundry company GenEdit: CRISPR for human use

CITRIS Foundry company GenEdit founders Kunwoo Lee and Hyo Min Park, coauthors of a study demonstrating the effectiveness of CRISPR-Cas9 gene-editing technology in mice, aim to translate the technology for human use. Says bioengineering professor Niren Murthy, lead author of the study along with colleague Irina Conboy, the technology “has the potential to develop into a therapeutic for treating genetic diseases,” which cause devastating levels of human mortality and morbidity.

Read the full story:  “CRISPR-Gold fixes Duchenne muscular dystrophy mutation in mice“, by Brett Israel, Berkeley News, October 3, 2017

Learn more about the CITRIS Foundry at
Learn more about GenEdit at

Related Video from CITRIS Media: